HomeCompareBND vs MRK

BND vs MRK: Dividend Comparison 2026

BND yields 3.91% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $4.9K in total portfolio value
10 years
BND
BND
● Live price
3.91%
Share price
$73.48
Annual div
$2.88
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.8K
Annual income
$503.36
Full BND calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — BND vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNDMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BND + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BND pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BND
Annual income on $10K today (after 15% tax)
$332.75/yr
After 10yr DRIP, annual income (after tax)
$427.86/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $379.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BND + MRK for your $10,000?

BND: 50%MRK: 50%
100% MRK50/50100% BND
Portfolio after 10yr
$28.3K
Annual income
$726.83/yr
Blended yield
2.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BND
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BND buys
1
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNDMRK
Forward yield3.91%3.25%
Annual dividend / share$2.88$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$25.8K$30.7K
Annual income after 10y$503.36$950.29
Total dividends collected$4.5K$6.1K
Payment frequencyquarterlyquarterly
SectorETFHealthcare

Year-by-year: BND vs MRK ($10,000, DRIP)

YearBND PortfolioBND Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,091$391.47$11,192$351.54$101.00MRK
2$12,274$405.79$12,524$392.70$250.00MRK
3$13,552$419.66$14,015$438.65$463.00MRK
4$14,934$433.07$15,682$489.96$748.00MRK
5$16,426$446.01$17,547$547.23$1.1KMRK
6$18,034$458.46$19,632$611.16$1.6KMRK
7$19,767$470.42$21,963$682.53$2.2KMRK
8$21,632$481.88$24,571$762.18$2.9KMRK
9$23,639$492.86$27,486$851.08$3.8KMRK
10$25,797$503.36$30,745$950.29$4.9KMRK

BND vs MRK: Complete Analysis 2026

BNDETF

The fund’s investment objective is to seek to track the performance of a broad, market-weighted bond index. The fund generally: Provides broad exposure to the taxable investment-grade U.S. dollar-denominated bond market, excluding inflation-protected and tax-exempt bonds. Offers relatively high potential for investment income; share value tends to rise and fall modestly. May be more appropriate for medium- or long-term goals where you’re looking for a reliable income stream. Is appropriate for diversifying the risks of stocks in a portfolio.

Full BND Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this BND vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BND vs SCHDBND vs JEPIBND vs OBND vs KOBND vs MAINBND vs JNJBND vs ABBVBND vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.